Revumenib (SNDX‐5613) is a potent, oral, small‐molecule inhibitor of the menin–KMT2A complex, which in single‐agent early Phase 1 and 2 trials [17, 18] showed impressive safety and efficacy in patients with R/R KMT2A‐r leukemias. Here, KMT2A is linked to leukemia.